[HTML][HTML] Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use …
KD Argyri, DD Dionysiou, FD Misichroni… - Biology direct, 2016 - Springer
Background Antiangiogenic agents have been recently added to the oncological
armamentarium with bevacizumab probably being the most popular representative in …
armamentarium with bevacizumab probably being the most popular representative in …
[HTML][HTML] Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use …
KD Argyri, DD Dionysiou… - Biology …, 2016 - biologydirect.biomedcentral.com
Antiangiogenic agents have been recently added to the oncological armamentarium with
bevacizumab probably being the most popular representative in current clinical practice …
bevacizumab probably being the most popular representative in current clinical practice …
Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of …
KD Argyri, DD Dionysiou, FD Misichroni… - Biology Direct, 2016 - infona.pl
Background Antiangiogenic agents have been recently added to the oncological
armamentarium with bevacizumab probably being the most popular representative in …
armamentarium with bevacizumab probably being the most popular representative in …
[PDF][PDF] Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of …
KD Argyri, DD Dionysiou, FD Misichroni… - 2016 - core.ac.uk
Background: Antiangiogenic agents have been recently added to the oncological
armamentarium with bevacizumab probably being the most popular representative in …
armamentarium with bevacizumab probably being the most popular representative in …
[PDF][PDF] Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of …
KD Argyri, DD Dionysiou, FD Misichroni… - 2016 - cyberleninka.org
Background: Antiangiogenic agents have been recently added to the oncological
armamentarium with bevacizumab probably being the most popular representative in …
armamentarium with bevacizumab probably being the most popular representative in …
Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of …
KD Argyri, DD Dionysiou, FD Misichroni… - Biology …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Antiangiogenic agents have been recently added to the oncological
armamentarium with bevacizumab probably being the most popular representative in …
armamentarium with bevacizumab probably being the most popular representative in …
Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of …
KD Argyri, DD Dionysiou, FD Misichroni… - Biology …, 2016 - search.proquest.com
Background Antiangiogenic agents have been recently added to the oncological
armamentarium with bevacizumab probably being the most popular representative in …
armamentarium with bevacizumab probably being the most popular representative in …
[PDF][PDF] Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of …
KD Argyri, DD Dionysiou, FD Misichroni… - 2016 - researchgate.net
Background: Antiangiogenic agents have been recently added to the oncological
armamentarium with bevacizumab probably being the most popular representative in …
armamentarium with bevacizumab probably being the most popular representative in …
Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of …
KD Argyri, DD Dionysiou, FD Misichroni… - Biology …, 2016 - search.ebscohost.com
Background: Antiangiogenic agents have been recently added to the oncological
armamentarium with bevacizumab probably being the most popular representative in …
armamentarium with bevacizumab probably being the most popular representative in …
[HTML][HTML] Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use …
KD Argyri, DD Dionysiou, FD Misichroni… - Biology …, 2016 - ncbi.nlm.nih.gov
Background Antiangiogenic agents have been recently added to the oncological
armamentarium with bevacizumab probably being the most popular representative in …
armamentarium with bevacizumab probably being the most popular representative in …